Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

Table 2

Chemotherapy regimens administered following disease progression after the first-line chemotherapy.

	Second line	More than third line	Total
CBDCA + etoposide rechallenge	1	1	2
CBDCA + irinotecan	15	9	24
Amrubicin	25	5	31
Topotecan	2	3	6
Others	0	0	0

CBDCA: carboplatin.